The American Journal of Medicine
Volume 122, Issue 10 , Pages 919-930 , October 2009

Incidence of Thrombocytopenia in Hospitalized Patients with Venous Thromboembolism

  • Paul D. Stein, MD

      Affiliations

    • Research and Advanced Studies Program, Michigan State University, College of Osteopathic Medicine, Detroit Medical Center Campus, Detroit, Mich
    • Corresponding Author InformationRequests for reprints should be addressed to Paul D. Stein, MD, 44405 Woodward Avenue, Pontiac, MI 48341-5023
    • ,
  • Russell D. Hull, MBBS, MSc

      Affiliations

    • Department of Medicine, University of Calgary, Alberta, Canada
    • ,
  • Fadi Matta, MD

      Affiliations

    • Research and Advanced Studies Program, Michigan State University, College of Osteopathic Medicine, Detroit Medical Center Campus, Detroit, Mich
    • ,
  • Abdo Y. Yaekoub, MD

      Affiliations

    • Department of Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, Mich
    • ,
  • Jane Liang, MSc

      Affiliations

    • Department of Medicine, University of Calgary, Alberta, Canada

References 

  1. Hirsh J, Warkentin TE, Raschke R, et al. considerations, monitoring, efficacy, and safety. Chest. 1998;114(5 Suppl):489S–510S
  2. US Department of Health and Human Services, Public Health Service, National Center for Health Statistics. National Hospital Discharge Survey 1979-1999 Multi-year Public-Use Data File Documentation. http://www.cdc.gov/nchs/about/major/hdasd/nhds.htmAccessed November 10, 2008
  3. Scottish Intercollegiate Guidelines Network (SIGN). www.sign.ac.uk/methodology/risk.xlsAccessed March 4, 2009
  4. Zeuner A, Signore M, Martinetti D, et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007;67:4767–4773
  5. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242–1246
  6. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518–2524
  7. Lindhoff-Last E, Nakov R, Misselwitz F, et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol. 2002;118:1137–1142
  8. Oliveira GB, Crespo EM, Becker RC, et al. Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008;168:94–102
  9. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. Cardiol Clin. 2008;26:145–155
  10. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710–2715
  11. Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a meta-analysis. Chest. 2007;132:1131–1139
  12. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism (The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire). N Engl J Med. 1997;337:663–669
  13. Merli G, Spiro TE, Olsson CG, et al. Enoxaparin Clinical Trial Group Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191–202
  14. Prandoni P, Carnovali M, Marchiori A Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med. 2004;164:1077–1083
  15. Nurmohamed MT, Verhaeghe R, Haas S, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg. 1995;169:567–571
  16. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement (A randomized trial). Arch Orthop Trauma Surg. 1992;111:110–120
  17. Heilmann L, Kruck M, Schindler AE. Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin. [German] Geburtshilfe Frauenheilkd. 1989;49:803–807
  18. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (Prophylaxis in Medical Patients with Enoxaparin Study Group). N Engl J Med. 1999;341:793–800
  19. Forette B, Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects (Study of tolerance). Presse Med. 1995;24:567–571
  20. Rao AK, White GC, Sherman L, et al. Low incidence of thrombocytopenia with porcine mucosal heparin (A prospective multicenter study). Arch Intern Med. 1989;149:1285–1288
  21. Leizorovicz A, Cohen AT, Turpie AG, et al. PREVENT Medical Thromboprophylaxis Study Group Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  22. Prandoni P, Siragusa S, Girolami B, Fabris F BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106:3049–3054
  23. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135:858–869
  24. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955–2959
  25. Büller HR, Davidson BL, Decousus H, et al. Matisse Investigators Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702
  26. Powers PJ, Cuthbert D, Hirsh J. Thrombocytopenia found uncommonly during heparin therapy. JAMA. 1979;241:2396–2397
  27. Ansell J, Slepchuk N, Kumar R, et al. Heparin induced thrombocytopenia: a prospective study. Thromb Haemost. 1980;43:61–65
  28. Ansell JE, Price JM, Shah S, Beckner RR. Heparin-induced thrombocytopenia (What is its real frequency?). Chest. 1985;88:878–882
  29. Bailey RT, Ursick JA, Heim KL, et al. Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug Intell Clin Pharm. 1986;20:374–378
  30. Bell WR, Royall RM. Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med. 1980;303:902–907
  31. Cipolle RJ, Rodvold KA, Seifert R, et al. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit. 1983;5:205–211
  32. Green D, Martin GJ, Shoichet SH, et al. Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. Am J Med Sci. 1984;288:60–64
  33. Powers PJ, Kelton JG, Carter CJ. Studies on the frequency of heparin-associated thrombocytopenia. Thromb Res. 1984;33:439–443
  34. Bossuyt PM, Reitsman JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1–W12
  35. Romano PS, Mark DH. Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care. 1994;32:81–90
  36. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737–740
  37. Kniffin WD, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861–866
  38. Stein PD, Kayali F, Olson RE, et al. Pulmonary thromboembolism in Asian/Pacific Islanders in the United States: Analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med. 2004;116:435–442
  39. Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence, and implications. Cardiovasc Surg. 1997;5:77–81
  40. Stein PD, Henry JW. Prevalence of acute pulmonary embolism in a general hospital and at autopsy. Chest. 1995;108:978–981
  41. Stein PD, Patel KC, Kalra NJ, et al. Estimated incidence of acute pulmonary embolism in a community/teaching general hospital. Chest. 2002;121:802–805
  42. Hsia DC, Crushat WM, Fagan AB, et al. Accuracy of diagnostic coding for medicare patients under the prospective payment system. N Engl J Med. 1988;318:352–355
  43. Hillbom M, Erilä T, Sotaniemi K, et al. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand. 2002;106:84–92
  44. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement (A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group). J Bone Joint Surg Am. 1994;76:3–14
  45. Ganzer D, Gutezeit A, Mayer G. Potentials risks in drug prevention of thrombosis—low-molecular-weight heparin versus standard heparin. [German] Z Orthop Ihre Grenzgeb. 1999;137:457–461
  46. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106:2921–2922
  47. McLeod RS, Geerts WH, Sniderman KW, et al. Canadian Colorectal Surgery DVT Prophylaxis Trial investigators Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg. 2001;233:438–444
  48. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303:543–548
  49. Mahlfeld K, Franke J, Schaeper O, et al. Heparin-induced thrombocytopenia as a complication of postoperative prevention of thromboembolism with unfractionated heparin/low molecular weight heparin after hip and knee prosthesis implantation. [German] Unfallchirurg. 2002;105:327–331
  50. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–1335
  51. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76:195–199
  52. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home (The Tasman Study Group). N Engl J Med. 1996;334:682–687
  53. Harenberg J, Schmidt JA, Koppenhagen K, et al. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis (EASTERN Investigators). Thromb Haemost. 2000;83:652–656
  54. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677–681
  55. Kirchmaier CM, Wolf H, Schäfer H, et al. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis (Certoparin-Study Group). Int Angiol. 1998;17:135–145
  56. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol. 2001;185:148–152
  57. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668–672
  58. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2001;108:1134–1140
  59. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients—a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr. 1999;158(Suppl 3):S130–S133
  60. Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost. 2004;91:719–724
  61. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937–2941

 Funding: None.

 Conflict of Interest: Russell Hull has received research support from Sanofi-Aventis and Leo-pharma. He has been on advisory boards for Sanofi-Aventis, Boehringer Ingelheim, Bayer, and Pfizer. None of the authors have any conflict of interest with the content of this article.

 Authorship: All authors had access to the data and a role in writing the manuscript.

PII: S0002-9343(09)00437-9

doi: 10.1016/j.amjmed.2009.03.026

The American Journal of Medicine
Volume 122, Issue 10 , Pages 919-930 , October 2009

Article Tools

* Image Usage & Resolution